Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 3/20 | 0.60 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | GSK3A | P49840 | 2/20 | 0.47 |
| ▸ | GSK3B | P49841 | 2/20 | 0.47 |
| ▸ | BCHE | P06276 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | KAT2B | Q92831 | 4/20 | 0.43 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.41 |
| ▸ | BAK1 | Q16611 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2556569 | 0.81 | MAPT (0.62) | PKMMAPTLMNAALDH1A1KAT2B | |
| SCHEMBL1048773 | 0.79 | GSK3A (0.49) | PKMLMNAALDH1A1GSK3AGSK3B | |
| SCHEMBL1052684 | 0.78 | GSK3A (0.48) | PKMMAPTLMNAALDH1A1GSK3A | |
| SCHEMBL17735529 | 0.76 | MAPT (0.55) | MAPTLMNAALDH1A1GSK3AGSK3B | |
| SCHEMBL12290345 | 0.76 | MAPT (0.64) | PKMMAPTALDH1A1 | |
| SCHEMBL4122712 | 0.76 | PKM (0.73) | PKMMAPTLMNAALDH1A1CTSB | |
| SCHEMBL14334902 | 0.75 | MAPT (0.60) | PKMMAPTLMNAALDH1A1KAT2B | |
| SCHEMBL29959789 | 0.75 | MAPT (0.60) | PKMMAPTLMNAALDH1A1KAT2B | |
| SCHEMBL4844382 | 0.75 | ALDH1A1 (0.70) | PKMMAPTLMNAALDH1A1 | |
| SCHEMBL2556480 | 0.74 | MAPT (0.54) | PKMMAPTLMNAALDH1A1KAT2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLOUNT KENNETH F (US) | 2012-11-22 | — | — | US | disclosed |
| EP-2448926-A1 | FLAVIN DERIVATIVES | Biorelix, Inc. (US) | 2012-05-09 | — | — | EP | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
| WO-2011008247-A1 | FLAVIN DERIVATIVES | BIORELIX, INC. (US) | 2011-01-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295903-A1 | FLAVIN DERIVATIVES | BLVRB, FLAD1, FDPS | PKM 4015/4885MAPT 4674/4885LMNA 3529/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.